Christopher Senner

Track

Insider profile

Currently holds positions in Exelixis Inc and Quince Therapeutics Inc

Performance

Overall performance
3.1
Performance over holding periods
3.1
30 days 90 days 120 days
Average return 4% 8.2% 15.1%
Success rate 72% 68% 82%
Transactions
11 0% Buy
34 71% Buy
47 69% Buy
Ranking by holding-period performance

Positions

Position Company Period
Chief Financial Officer, Executive Vice President Exelixis Inc July 15, 2015 -
Independent Director Quince Therapeutics Inc March 1, 2019 -
Christopher Senner's trades of Exelixis Inc's stock


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date Company B/S Transaction type Nb. shares
Price
Value 		Number of shares Price Value Details
2026-05-19 2026-05-18
US Exelixis Inc (EXEL)
S Sale
16,678 +31.5%
265.22
US$4,879,480 		16,678 +31.5% 265.22 US$4,879,480
2026-05-18 2026-05-18
US Exelixis Inc (EXEL)
PrS Proposed sale
20,100
171.20
US$1,178,513 		20,100 171.20 US$1,178,513
2026-02-18 2026-02-17
US Exelixis Inc (EXEL)
S Sale
13,346 -39.6%
13.09
US$630,668 		13,346 -39.6% 13.09 US$630,668
2026-02-17 2026-02-17
US Exelixis Inc (EXEL)
PrS Proposed sale
30,617
43.67
US$1,337,035 		30,617 43.67 US$1,337,035
2026-02-18 2026-02-13
US Exelixis Inc (EXEL)
S Sale
34,278 -3.2%
43.00
US$1,473,954 		34,278 -3.2% 43.00 US$1,473,954
2026-02-13 2026-02-13
US Exelixis Inc (EXEL)
PrS Proposed sale
34,278
43.00
US$1,473,964 		34,278 43.00 US$1,473,964
2025-05-16 2025-05-16
US Exelixis Inc (EXEL)
PrS Proposed sale
100,000
46.00
US$4,600,000 		100,000 46.00 US$4,600,000
2025-05-16 2025-05-16
US Exelixis Inc (EXEL)
S Sale
100,000 -9.4%
46.00
US$4,600,000 		100,000 -9.4% 46.00 US$4,600,000
2025-02-26 2025-02-24
US Exelixis Inc (EXEL)
S Sale
29,314 -3.6%
36.14
US$1,059,408 		29,314 -3.6% 36.14 US$1,059,408
2025-02-24 2025-02-24
US Exelixis Inc (EXEL)
PrS Proposed sale
29,314
36.14
US$1,059,370 		29,314 36.14 US$1,059,370
2024-08-09 2024-08-09
US Exelixis Inc (EXEL)
PrS Proposed sale
125,000
27.17
US$3,396,250 		125,000 27.17 US$3,396,250
2024-08-09 2024-08-09
US Exelixis Inc (EXEL)
S Sale
125,000 -14.8%
27.19
US$3,398,750 		125,000 -14.8% 27.19 US$3,398,750
2023-08-07 2023-08-04
US Exelixis Inc (EXEL)
S Sale
60,000 -9.5%
20.68
US$1,240,800 		60,000 -9.5% 20.68 US$1,240,800
2023-08-07 2023-08-03
US Exelixis Inc (EXEL)
S Sale
60,000 -9.5%
20.51
US$1,230,600 		60,000 -9.5% 20.51 US$1,230,600
2023-08-03 2023-08-03
US Exelixis Inc (EXEL)
PrS Proposed sale
120,000
19.75
US$2,370,511 		120,000 19.75 US$2,370,511
2021-01-14 2021-01-12
US Exelixis Inc (EXEL)
PlS Planned sale
30,000 -10.9%
25.00
US$750,000 		30,000 -10.9% 25.00 US$750,000
2020-10-09 2020-10-08
US Exelixis Inc (EXEL)
PlS Planned sale
10,000 -7.3%
25.00
US$250,000 		10,000 -7.3% 25.00 US$250,000
2020-09-15 2020-09-15
US Exelixis Inc (EXEL)
PlS Planned sale
20,000 -13.5%
25.00
US$500,000 		20,000 -13.5% 25.00 US$500,000
2020-05-08 2020-05-08
US Exelixis Inc (EXEL)
S Sale
78,583 -39.4%
25.81
US$2,028,227 		78,583 -39.4% 25.81 US$2,028,227
2020-05-08 2020-05-07
US Exelixis Inc (EXEL)
S Sale
21,417 -15.1%
25.80
US$552,559 		21,417 -15.1% 25.80 US$552,559
2019-05-03 2019-05-03
US Exelixis Inc (EXEL)
PlS Planned sale
36,261 -24.4%
20.70
US$750,603 		36,261 -24.4% 20.70 US$750,603
2018-11-30 2018-11-30
US Exelixis Inc (EXEL)
S Sale
8,791 -5.6%
19.70
US$173,183 		8,791 -5.6% 19.70 US$173,183
2017-03-03 2017-03-03
US Exelixis Inc (EXEL)
PlS Planned sale
11,000 -9.9%
22.80
US$250,800 		11,000 -9.9% 22.80 US$250,800